4DMedical (ASX:4DX) said medical device firm Olympus launched its SeleCT Screening population-level emphysema screening program using the 4DMedical's lung density analysis technology, according to a Wednesday Australian bourse filing.
The solution reviews existing computed tomography (CT) scans to identify patients with advanced emphysema who may be candidates for bronchoscopic lung volume reduction.
The program established Olympus as a key partner and scaled 4DMedical's lung analysis technology across major US health systems, the filing added.
4DMedical's shares fell 3% in recent trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.